Cocrystal Pharma presents CDI-988 data at ICAR 2026; Phase 1b norovirus study fully enrolled in stage 1

Cocrystal Pharma, Inc.

CDI-988 mechanism and Phase 1b human challenge study featured at ICAR 2026 in Prague.
Phase 1b study fully enrolled first cohort to assess infectivity of GII.2 Snow Mountain Virus inoculum.
CDI-988 is first oral direct-acting antiviral for norovirus; targets conserved 3CL protease across strains.
FDA Fast Track designation granted for CDI-988 for norovirus treatment and prophylaxis.
No approved treatments or vaccines for norovirus; $60 billion annual economic burden.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.